Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.

Slides:



Advertisements
Similar presentations
Domestication and Implementation Package B The duty to prevent torture and other ill treatment © The Article 5 Initiative, 2013.
Advertisements

Vienna, Austria 4 September 2014 Stefano Berterame, Chief Narcotics Control and Estimates Section Secretariat of the International Narcotics Control Board.
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
Childcare Issues in the Young Persons Programme Deirdre Carey Social Worker The Drug Treatment Centre Board.
Sources Of Human Rights
Human Rights and Palliative Care: A Primer Kiera Hepford Open Society Foundations Costing for Change Seminar Brasov, Romania October 26 th - 28 th, 2011.
Right to an Effective Remedy:
National Institute on Drug Abuse P rescription D rug A buse: An Escalating Public Health Threat P rescription D rug A buse: An Escalating Public Health.
Bylaw on drug demand reduction in Serbia. Bylaw(s) - principles  should be based on existing law(s)  should complement existing laws  should not be.
PSK Annual Conference 2008 Palliative care medicine: A balanced approach to opioid availability and safe use in Kenya Presenter: Dr. Bilha Kiama-Murage.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
WHO GLOBAL ALCOHOL STRATEGY
DEALING WITH GOVERNMENT SCRUTINY OF PAIN MANAGEMENT BY PRIMARY CARE PHYSICIANS How To Anticipate And Avoid Government Interference With This Crucial Area.
Model regulations on demand reduction in Europe Bylaw on drug demand reduction.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Development of a Road Map to Controlled Substance Diversion Prevention Rene Cronquist, RN, J.D. Director of Practice and Policy Minnesota Board of Nursing.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Essential elements for regulation Bylaw on drug demand reduction.
Working with UICC’s 800+ member organisations in 155 countries, the McCabe Centre aims to build legal capacity globally. Based at CCV in Melbourne, Australia.
Asia-Pacific High-level Meeting on HIV and AIDS The Asia-Pacific High-level Intergovernmental Meeting on the Assessment of Progress against Commitments.
Dr Godfrey Xuereb Team Leader Surveillance and Population-based Prevention Department for the Prevention of NCDs A comprehensive global monitoring framework.
IAEA International Atomic Energy Agency Overview of legal framework Regional Workshop - School for Drafting Regulations 3-14 November 2014 Abdelmadjid.
Designing a drug control system that balances access with prevention and control of misuse: What should it look like? Martha Maurer, MSSW, MPH, PhD Pain.
Investigation and case planning Your responsibilities under the Children Act 1989 Brayne & Carr: Law for Social Workers: 10e Chapter 9.
Current System of Drug Control In Georgia Prof. D. Kordzaia – Georgian National Association for Palliative Care VIENNA - March 5-6, 2013 “Making Oral Opioids.
“Improving opioid availability through advocacy” Experience from Serbia Snežana Bošnjak International Pain Policy Fellow ( ) Institute for Oncology.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,
Ministry of Health of the Republic of Armenia Feb 2013.
WHO Access to Controlled Medications Programme & Ensuring balance in national policies on controlled substances Barbara Milani, Technical Officer Department.
Twinning Project Implementation of Strategy for Fight Against Drugs in Serbia Kick off and Assessment November 2012 Belgrade.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
VICTIM SUPPORT: The International Context Bali Process Workshop on Victim Support 7 – 9 November 2006 Michel Bonnieu, Senior Regional Legal Advisor UNODC.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
Methods to Evaluate and Improve National Policy: Focus on 2011 WHO Guidelines and PPSG Global Policy Evaluation Aaron M. Gilson, MS, MSSW, PhD Research.
“” “Balance” Jim Cleary, MD Associate Professor of Medicine Director, Palliative Care Medicine, UW Hospital & Clinics Director, WHO Collaborating Center.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
Presented by Esme Grant, J.D. U.S. International Council on Disabilities 1.
Global Challenges in Cancer Pain S. Lawrence Librach MD,CCFP,FCFP Professor, Department of Family & Community Medicine Sun Life Financial Chair & Director,
POSTECH H uman S ystem D esign Lab oratory Universal Design Handbook Chp. 11: United Nations standards and rules Thu. 이 동 훈.
Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.
"Perspectives of former International Pain Policy Fellows" Prof. Snežana Bošnjak, MD, PhD Institute for Oncology and Radiology of Serbia (IORS) Belgrade,
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
WHO activities related to WHA58.26 | 11. August |1 | WHA resolution on alcohol (2005): background and follow up activities by the WHO Secretariat.
Preventing drug diversion: Principles and concepts International Pain Policy Fellowship August 7, 2012 David E. Joranson Distinguished Scientist, Founder.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
TRANSDISCIPLINARY FOUNDATION II: TREATMENT KNOWLEDGE Contributor: Lori Phelps Lori L. Phelps California Association for Alcohol/Drug Educators, 2015 Chapter.
Building International Drug Policy Consensus and Conflict – the 2010 Commission on Narcotic Drugs
Office of Special Projects Issues arising from the Second Review Conference on Safety and Security at Chemical Plants and Relationships with CWC stakeholders.
Gilberto Gerra Drug Prevention and Health Branch Access to controlled drugs for medical purposes: a commitment for the international community.
دکترارتین کمالی ثابتی ( متخصص پزشکی قانونی ومسمومیتها )
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
1 M O N T E N E G R O Negotiating Team for the Accession of Montenegro to the European Union Working Group for Chapter 29 – Customs union Bilateral screening:
Feedback by NGOs to the NCD Alliance on the WHO Discussion Paper on a comprehensive global monitoring framework and voluntary global targets for prevention.
World Health Organization Non-communicable disease prevention and control: key messages 1.Non-communicable diseases are a major public health and socio-
ASSESSING POSSIBLE INCENTIVES TO ENCOURAGE THE PRIVATE SECTOR TO INVEST IN ENVIRONMENTALLY SOUND MANAGEMENT Dr. Leila Devia, BCRC Argentina Ross Bartley,
Denis G. Patterson, DO ECHO Project April 20, 2016 CDC Guidelines for Prescribing Opioids for Chronic Pain.
Medication Assisted Treatment
CDA PRESENTATION TO PORTFOLIO COMMITTEE ON SOCIAL DEVELOPMENT 2005/03/09 PROF RATAEMANE.
Legal and Regulatory Issues in Pain Management
Nuclear and Treaty Law Section Office of Legal Affairs
Opioid Prescribing & Monitoring
Right to an Effective Remedy:
Indispensable, adequately provided and not unduly restricted
Disability Rights and the United Nations: Developing Hard Law
INCB PERMITS & REQUIREMENTS FOR ESTIMATES.
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
Right to an Effective Remedy:
A FRIENDLY REMINDER ON OTC DRUGS. DRUG REGULATIONS IN THE PHILIPPINES.
Presentation transcript:

Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade and distribution of narcotics; each state must provide: estimates of its need for medical and scientific purposes; data on stocks, production, manufacture, consumption, import and export. export and import licences are required medical prescriptions are required for dispensation to patients

Single Convention on Narcotic Drugs overseen / administered by Vienna-based international agencies UN Commission on Narcotic Drugs International Narcotics Control Board UN Office on Drugs and Crime

Single Convention on Narcotic Drugs ‘Recognizing that the medical use of narcotic drugs continues to be indispensable for the relief of pain and suffering and that adequate provision must be made to ensure the availability of narcotic drugs for such purposes’ BUT – in practice the focus has been on preventing diversion and misuse

Progress since 2010 international recognition of the need for action Vienna-based agencies UN Pol Dec on NCDs WHA palliative care resolution

CND Resolution 53/4, March 2010 a landmark resolution historically the focus has been on preventing diversion of controlled substances The resolution affirmed the principle for balance

CND Resolution 53/4 - availability stressing the importance of promoting adequate availability of internationally controlled licit drugs for medical and scientific purposes while preventing their diversion and abuse recalling the Single Convention in which parties recognized that medical use of narcotic drugs continued to be indispensable for relief of pain and suffering and that adequate provision must be made to ensure availability of narcotic drugs for such purposes

CND Resolution 53/4 - balance affirming that the international drug control conventions seek to achieve a balance between ensuring availability of narcotic drugs and psychotropic substances under international control for medical and scientific purposes and preventing their diversion and abuse

Developments since 53/4 significant publications Report on Availability (2010) Ensuring Balance guidelines (2011) Discussion Paper (2011)

Developments since 53/4 CND Resolution 54/6 Model law review and revision Political Declaration on the prevention and control of NCDs WHA Palliative Care Resolution Global Monitoring framework including essential medicines target

UNODC Discussion Paper ‘UNODC has long worked proactively to assist Member States to implement the diversion and abuse prevention aspect of their obligations under the drug Conventions. This should be, and will remain, an essential element of UNODC’s work, but the Office will also focus equally on all elements necessary to guarantee availability and accessibility with particular attention to avoiding any control measures unintentionally impeding high quality medical treatment.’

CND Resolution 54/6, March 2011 follow-up resolution to CND53/4

CND Resolution 54/6 recalling 53/4 aimed at promoting adequate availability of internationally controlled drugs for medical and scientific purposes while preventing their diversion and abuse note the order promoting adequate availability while preventing diversion and abuse this is now the established formulation

UNODC model law review and revision

Revisions to model laws use of neutral terminology to describe drugs that have medical or scientific uses but can cause harm when misused eg the Schedule in which morphine is listed described as including ‘[d]rugs and substances having a medical and/or scientific use which should be subject to control in view of the harms that their non-medical and/or non- scientific use can cause’

Revisions to model laws contrasts with the previous wording, which referred to ‘[s]trictly controlled substances and plants having a medical use’, and ‘[s]ubstances with a high potential risk to public health but having a medical use’ (emphasis added) under the previous formulation, concern about the risk of misuse predominated over the need to ensure appropriate medical treatment

UNODC ‘model’ law COMPARE to the previous terminology: "drug of abuse" means a prohibited drug, a high- risk drug, or a risk drug, and includes a preparation; "high-risk drug" means a substance listed in Schedule II of this Act

UNODC ‘model’ law drug dependent person, in relation to a drug of abuse or analogue, means any person who has a condition such that: … (ii) cessation of the administration of the drug is likely to result in the person experiencing symptoms of mental or physical distress or disorder

Further developments

Global monitoring framework on NCDs adopted by World Health Assembly May 2013 voluntary target for % availability in both public and private facilities of basic technologies and generic essential medicines required to treat major NCDs

Global monitoring framework on NCDs adopted by World Health Assembly May 2013 indicator for health system response access to palliative care assessed by morphine-equivalent consumption of strong opioid analgesics (excluding methadone) per death from cancer selected as effective proxy measurement for palliative care development for all life-threatening illnesses, including NCDs

WHA Palliative Care Resolution

UN General Assembly Special Session on Drugs 2016

Links to relevant documents at to-medicines/access-to-opioid-analgesics